Our reviews

The 'Full list' option in the menu below will give you an up-to-date list of published reviews, registered titles and published protocols coordinated and edited by Cochrane Childhood Cancer. 

Our Reviews

Full list:

By subtopic:

Diagnosis (3)
Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung and lymph node metastases in rhabdomyosarcoma (protocol stage)
Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) for detecting metastases of Ewing sarcoma (protocol stage)
123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma
Treatment (19)
Anti-GD2 antibody-containing immunotherapy post-consolidation therapy for people with high-risk neuroblastoma treated with autologous hematopoietic stem cell transplantation (protocol stage)
Antibody therapies for lymphoma in children
Chemotherapy for children with medulloblastoma
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients
Different infusion durations for preventing platinum-induced hearing loss in children with cancer
Focal laser treatment in addition to chemotherapy for retinoblastoma
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma
High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents and young adults with first recurrence of Ewing sarcoma (protocol stage)
High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents and young adults with metastatic Ewing sarcoma (protocol stage)
High-dose chemotherapy for children and young adults with stage IV rhabdomyosarcoma
Intracystic bleomycin for cystic craniopharyngiomas in children
Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma
Methotrexate for high-grade osteosarcoma in children and young adults
Minimally invasive surgery versus open surgery for the treatment of solid abdominal and thoracic neoplasms in children
Radiotherapy for diffuse brainstem glioma in children and young adults
Rapid COJEC versus standard induction therapies for high-risk neuroblastoma
Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation
Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission
Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer
Supportive care: therapy-related side effects during treatment (22)
Antibiotic and other lock treatments for tunnelled central venous catheter-related infections in children with cancer
Clinical heart failure in children, adolescents and young adults treated with anthracyclines and/or irradiation involving the heart region (protocol stage)
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy
Different infusion durations for preventing platinum-induced hearing loss in children with cancer
Medical interventions for the prevention of platinum-induced hearing loss in children with cancer
Cardioprotective interventions for cancer patients receiving anthracyclines
Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood
Empirical antibiotic therapy for febrile neutropenia in pediatric cancer patients (protocol stage)
Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients
Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients
Influenza vaccination in children being treated with chemotherapy for cancer
Interventions other than anticoagulants and systemic antibiotics for prevention of central venous catheter-related infections in children with cancer
Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia
Nutritional support in children and young people with cancer undergoing chemotherapy
Physical exercise training interventions for children and young adults during and after treatment for childhood cancer
Physical therapy interventions, other than general physical exercise interventions, in children and adolescents before, during and following treatment for cancer (protocol stage)
Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters
Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia
Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Very early discharge versus early discharge versus non-early discharge in children with cancer and febrile neutropenia
Psychosocial care (1)
Interventions for promoting participation in shared decision-making for children with cancer
Palliative and terminal care (0)
Nursing care (0)
Late effects: therapy-related side effects after treatment (17)
Anti-GD2 antibody-containing immunotherapy post-consolidation therapy for people with high-risk neuroblastoma treated with autologous hematopoietic stem cell transplantation (protocol stage)
Breast cancer in female survivors of childhood, adolescent or young adult cancer after radiotherapy involving the chest for their primary malignancy (protocol stage)
Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood cancer and cancer in the reproductive age (protocol stage)
Clinical heart failure in children, adolescents and young adults treated with anthracyclines and/or irradiation involving the heart region (protocol stage)
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy
Cardioprotective interventions for cancer patients receiving anthracyclines
Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients
Platinum-induced hearing loss after treatment for childhood cancer
Nutritional interventions for survivors of childhood cancer
Physical exercise training interventions for children and young adults during and after treatment for childhood cancer
Physical therapy interventions, other than general physical exercise interventions, in children and adolescents before, during and following treatment for cancer (protocol stage)
Severe fatigue in childhood cancer survivors (protocol stage)
Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia
Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer
Hepatic late adverse effects after antineoplastic treatment for childhood cancer

New and Updated (in the latest issue of the CLib):